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Background: X-linked Ornithine Transcarbamylase deficiency (OTCD) is often unrecognized in adults, as clinical
manifestations are non-specific, often episodic and unmasked by precipitants, and laboratory findings can be normal
outside the acute phase. It may thus be associated with significant mortality if not promptly recognized and treated.
The aim of this study was to provide clues for recognition of OTCD in adults and analyze the environmental factors
that, interacting with OTC gene mutations, might have triggered acute clinical manifestations.
Methods: We carried out a clinical, biochemical and molecular study on five unrelated adult patients (one female and
four males) with late onset OTCD, who presented to the Emergency Department (ED) with initial fatal encephalopathy.
The molecular study consisted of OTC gene sequencing in the probands and family members and in silico
characterization of the newly detected mutations.
Results: We identified two new, c.119G>T (p.Arg40Leu) and c.314G>A (p.Gly105Glu), and three known OTC mutations.
Both new mutations were predicted to cause a structural destabilization, correlating with late onset OTCD. We also
identified, among the family members, 8 heterozygous females and 2 hemizygous asymptomatic males. Patients'
histories revealed potential environmental triggering factors, including steroid treatment, chemotherapy, diet changes
and hormone therapy for in vitro fertilization.
Conclusions: This report raises awareness of the ED medical staff in considering OTCD in the differential diagnosis of
sudden neurological and behavioural disorders associated with hyperammonemia at any age and in both genders. It
also widens the knowledge about combined effect of genetic and environmental factors in determining the phenotypic
expression of OTCD.
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Ornithine transcarbamylase deficiency (OTCD; OMIM
311250), the most common urea cycle disorder (UCD), is
caused by a defect of the mitochondrial ornithine trans-
carbamylase (OTC, EC 2.1.3.3). The mature OTC enzyme,
a trimer, catalyses the synthesis of citrulline from carbamyl
phosphate (CP) and ornithine (ORN) in the liver and
small intestine [1].
OTCD is an X-linked disorder due to deleterious muta-
tions in the OTC gene in Xp21.1 and is characterized by
high molecular heterogeneity with about 435 mutations
having been described (HGMD: http://www.biobase-
international.com/product/hgmd). Severe OTC gene mu-
tations with no residual enzyme activity in hemizygous
males lead to hyperammonemic coma in the neonatal
period or in early infancy, which is often fatal. Some
affected males may, however, exhibit a delayed onset of
the disease, the so called “late onset OTCD” (LO-OTCD)
[2]. The number of reported LO-OTCD patients is in-
creasing [3], but only a few had remained essentially
asymptomatic until acute onset in adulthood. In hemizy-
gous male patients the phenotype is determined by several
conditions, including the type of mutation but also other
yet unknown factors such as environment and/or other
genes. In heterozygous females phenotypic severity is also
influenced by the X-inactivation pattern [1].
Without early diagnosis and intervention, the prognosis
of OTCD with acute hyperammonemia is poor. The emer-
gency management of hyperammonemia is based on: a)
reversal of the catabolic state through glucose supplemen-
tation and halted protein intake, b) pharmacological
removal of ammonia by sodium benzoate, sodium pheny-
lacetate or sodium phenylbutyrate administration and c)
extracorporeal detoxification of ammonia by dialysis [4,5].
L-arginine and/or L-citrulline supplementation promote
ammonia excretion through the urea cycle [4]. Hypothermia
may be a neuroprotective measure, but its efficacy has not
yet been proven in randomized controlled trials [6]. Guide-
lines for the diagnosis and management of UCD have been
recently drawn up in order to provide a general consensus
to guide practitioners and set standards of care [4].
We report a clinical, biochemical and molecular study
of five adults with OTCD who developed de novo fatal
hyperammonemic encephalopathy. We also present the
in silico characterization of the newly detected OTC
gene mutations and discuss the environmental events
that, interacting with OTC mutations, might have trig-
gered acute clinical manifestations.
Methods
Patients
Patients were adults referred to our diagnostic laboratory
because of clinical suspicion of a UCD, and their relatives.
Informed consent to the investigation, according to theDeclaration of Helsinki and approved by the Human
Research Ethics Committee of the Meyer’s University
Hospital, was obtained from all subjects.
Biochemical assays
Plasma amino acid analysis was performed by ion-exchange
chromatography on a Biochrom 30 amino acid analyzer
(Cambridge, UK) using the manufacturer’s standard
protocol.
Quantification of orotic acid in urine was performed by
LC–MS/MS (Toronto, Canada) as previously described [7].
Detection of OTC gene mutations
Genomic DNA was isolated from peripheral blood using a
QIAsymphony instrument as recommended by the manu-
facturer (Qiagen, Hilden, Germany). The entire coding re-
gion and intron-exon boundaries of the OTC gene were
amplified by PCR as previously reported [8]. PCR frag-
ments were separated on a 2% agarose gel, visualized with
a UV transilluminator and then purified using Exo-SAP-
IT (USB Corporation, Cleveland, OH, U.S.A).
Mutation analysis was performed by direct sequen-
cing of the double-stranded purified products using the
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, U.S.A.). Sequencing reactions
were purified using Sephadex G-50 Fine (GE Healthcare,
Little Chalfont, UK) and capillary electrophoresis was per-
formed on ABI PRISM 3130 Genetic Analyser (Applied
Biosystems) as recommended by the manufacturer.
All mutations are described according to guidelines of
the Human Genomic Variation Society (HGVS) (http://
www.hgvs.org/mutnomen/) and using the NM_000531.3
and NP_000522.3 reference sequences (http://www.ncbi.
nlm.nih.gov/gene/).
Screening of new OTC mutations
The Human Gene Mutation Database (HGMD) (http://
www.biobase-international.com/product/hgmd) was ana-
lyzed for investigating the novelty of mutations identi-
fied. The two new point mutations were subsequently
examined in the 1000 Genomes project database (http://
browser.1000genomes.org/index.html). In addition, we
screened by sequencing analysis the OTC gene of 100
DNA samples from healthy males to estimate the fre-
quency of new mutations in the Italian population.
Bioinformatic analyses of new OTC mutations
We downloaded the crystal structure for human OTC
protein [PDB: 1OTH] for structural analysis of the mu-
tant OTC enzyme. The 2D structure boundaries and
solvent accessibility were calculated with the Stride pro-
gram [9].
Stability changes in OTC protein introduced by muta-
tions were predicted by IMutant 2.0 [10]. Structure-
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37°C.
Knowledge about catalytic residues and substrate bind-
ing sites was obtained from the literature [11,12]. Effects
of mutations on the trimeric protein were predicted
based on PDB entry 1FVO. Inter-residue contacts were
studied with the CSU program [13].
For conservation analysis, 18 homologous sequences (10
from eukaryotes and 8 from bacteria) were aligned by
MAFFT E-INS-I [14]. Conservation scores were obtained
from the ConSurf program (Bayesian paradigm) [15].
The pathogenicity and functional effects of the new OTC
mutations were evaluated by SNAP (http://rostlab.org/
services/snap/), PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph2/) and MutPred (http://mutpred.mutdb.org/). The
probability threshold for pathogenicity was set to the
default value 0.05 for all tools.
Results
Clinical and biochemical investigation
Four Italian men (Pts 1 to 4) and one woman (Pt 5),
aged 21 to 66 years, developed initial and fatal hyperam-
monemic encephalopathy due to undiagnosed LO-
OTCD. Their main clinical and laboratory findings are
summarized in Tables 1 and 2. Detailed case reports are
available in Additional file 1: Text S1.
At the time of the acute episodes, none of the patients
had a family history of metabolic disorders or had previ-
ous episodes of altered mental status. Interestingly, three
patients reported preferring a low-protein diet with large
amounts of vegetables.
The clinical course of acute expression of symptoms
was similar in all patients, starting with gastrointestinal
symptoms and/or impaired awareness, rapidly evolving
into deterioration of the mental status and coma within
5 days from onset. Noticeably, in addition to hyperam-
monemia, hypertransaminasemia and respiratory alkal-
osis were observed in all patients.
The suspicion of OTCD was biochemically based on
altered amino acid profiles and orotic aciduria, which is
crucial for distinguishing OTCD from carbamoyl phos-
phate synthetase I (CPS1) and N-acetylglutamate syn-
thase (NAGS) deficiencies.
After clinical/biochemical suspicion of UCD was
established, emergency management of hyperammone-
mia was started in 4/5 patients, but although in 3/5 pa-
tients ammonia levels returned to normal after UCD
therapy, exitus ensued.
Molecular investigation
We confirmed OTCD in all patients by post-mortem
OTC sequence analysis. We identified two novel muta-
tions, c.119G > T (p.Arg40Leu) and c.314G > A (p.Gly105-
Glu), and three previously reported mutations, c.119G >A(p.Arg40His), c.622G >A (p.Ala208Thr) and c.829C > T
(p.Arg277Trp). The results of molecular and computa-
tional analysis are summarized in Table 3.
None of the new genetic variants was present in the
1000 Genomes Project database or in the Italian control
population, suggesting that they are likely to be disease-
causing mutations. Noticeably, all three pathogenicity
prediction tools, e.g. SNAP, PolyPhen-2 and MutPred,
consistently classified both new variants as pathogenic
(see Additional file 2: Table S2).
The novel c.119G > T (p.Arg40Leu) mutation, identi-
fied at a hemizygous level in Pt 1, affects a CpG di-
nucleotide in the exon which is also involved in two
other known mutations, the c.118C > T (p.Arg40Cys)
[16] and c.119G > A (p.Arg40His) [17]. The Arg 40 is a
conserved residue of the polar/CP binding domain (resi-
dues 34–168 and 345–354) [11], is not in contact with
the active site and its side chain is exposed to the surface
(Figure 1A).
The novel c.314G > A (p.Gly105Glu) mutation was
identified at the hemizygous level in Pt 3. The same nu-
cleotide is also involved in the c.314G > T (p.Gly105Val)
mutation that had previously been identified in a female
with OCTD [18]. The Gly 105 is a conserved residue
mapping in a turn of polar/CP binding domain of the
OTC protein [11]. In the trimeric OTC enzyme the 105
position is located on the top of trimer interface and the
three amino acids would be close to each other in the
quaternary structure (Figure 1B).
All the known c.119G > A (p.Arg40His), c.622G > A (p.
Ala208Thr) and c.829C > T (p.Arg277Trp) mutations
have been previously reported in OTCD patients with
residual enzymatic activity [17,19,20].
After the probands’ characterization the molecular
study of the OTC gene was extended to family members
and led to identification of 8 heterozygous females and 2
additional hemizygous asymptomatic males (Table 3).
Retrospective analysis for potential environmental
triggering factors
The retrospective analysis of the patients’ histories re-
vealed a number of precipitating environmental factors,
including therapy with steroids (Pt 1), diet changes im-
plying poor feeding after dental surgery (Pt 2) and in-
creased dietary protein intake plus food additives (Pt 3),
chemotherapy (Pt 4) and hormone therapy for in vitro
fertilization (Pt 5).
Discussion
Clinical and biochemical clues
OTCD is traditionally identified in pediatric patients
[21], while late-onset presentations may remain latent
for many years and often go unrecognized. As a conse-
quence, mortality rates may be high if they are not
Table 1 Clinical findings of adult OTCD patients with fatal encephalopathy
Pt 1 (M) Pt 2 (M) Pt 3 (M) Pt 4 (M) Pt 5 (F)
ACUTE EPISODE
Age at fatal acute episode 45 y 44 y 21 y 66 y 34 y
Duration of fatal episode 9 d 30 d 15 d 5 d 22 d
Duration of coma 7 d 1 d (first coma); 7 d (second coma) 12 d 2 d 20 d
FAMILY HISTORY OF
METABOLIC DISORDERS
Negative Negative Negative Negative Negative
PAST MEDICAL HISTORY Cholecystectomy; Crohn disease;
Carpal tunnel syndrome; Sciatica
Chronic Hepatitis B with fluctuating
hypertransaminasemia and prothrombin
deficiency
Negative Hypertension; Colon cancer
(colectomy and oxaliplatin and
capecitabine drugs); Hiccup after
chemotherapy
Drowsiness during
menstruation
DIET PRACTISE Regular Vegetarian Diet rich in vegetables Diet rich in vegetables Regular
PROBABLE TRIGGERING
EVENT
Cortisone therapy for joint pains Diet change and poor feeding
(8 kg lost in a month) after dental surgery
Diet change: a meal of fish in
a Chinese restaurant
Chemotherapy (Oxaliplatin,
Capecitabine)
Infertility hormone
therapy and ICSI-ET,
but without an ongoing
pregnancy
MISDIAGNOSIS AT ONSET Depression; Unspecified
hepatopathy
Infectious disease; Intestinal
pseudo-obstruction; Portosystemic shunts
Poisoning; Infectious diseases;
Drug abuse
Poisoning; Ischemia; Cancer;
Hepatitis
Narcolepsy; Cancer
SIGN AND SYMTOMS OF
ACUTE EPISODE
Abdominal pain/Vomiting No/Yes Yes/Yes Yes/Yes No/No No/No
Headache/Vertigo Yes/Yes No/Yes No/No No/Yes No/No
Fever No Yes No No Yes
Food refusal Yes Yes No No No
Seizures No Yes No Yes Yes
Hepatomegaly No No No Mild No
Consciousness disturbances Confusion; Drowsiness; Coma
(2 d after onset)
Irritability; Confusion; Coma lasting
24 hours (5 d after onset); Subsequent
coma (20 d after)
Confusion; Drowsiness; Coma
(3 d after onset)
Slurred speech; Confusion;
Hallucinations; Drowsiness;
Coma (3 d after onset)
Drowsiness; Coma
(2 d after onset)
Abbreviations: M male, F female, y years, d days, ICSI-ET intra cytoplasmatic sperm injection - embryo transfer.
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Table 2 Laboratory findings and therapy of adult OTCD patients with fatal encephalopathy
Pt 1 (M) Pt 2 (M) Pt 3 (M) Pt 4 (M) Pt 5 (F)
LABORATORY DATA
Total bilirubin (mg/dl, n.v. <1.2) 1.4 5.4 7.9 Normal 2.8
ALT; AST (U/l, n.v. < 40) 62; 55 467; 226 128; 84 127; 97 81; 95
Ammonia (first measurement - maximum value, μmol/l,
n.v. 50–80)
153-411 369-845 156-377 251-1145 362-901
Respiratory alkalosis (n.v.: blood pH 7.35-7.45, pCO2 35-
45 mmHg, pO2 75-100 mmHg)
blood pH 7.47, −, − blood pH 7.54, pCO2 30,
pO2 142
blood pH 7.45,
pCO2 32,
pO2 202
blood pH 7.51,
pCO2 27, pO2 223
blood pH 7.51, pCO2 26, pO2 274
PGlutamine (μmol/l, n.v. 399–823) 2006 4580 Normal 1680 1060
PCitrulline (μmol/l, n.v. 17–53) Normal Normal 14 3 10
PLysine; PProline (μmol/l, n.v. 105–236; 117–332) 702; Normal 900; 667 - - 462; Normal
UOrotic acid excretion (mmol/mol creatinine, n.v. 0.2-1.1) 378 34 Normal 234 136
Neuroimaging Normal at onset (CT);
Cerebral edema
(CT, 2 d later)
Normal at onset (CT);
Cerebral edema
(CT, 3rd d of the
second coma)
Normal at onset (CT);
Cerebral edema
(CT, 3 d later)
Normal at onset
(CT and MRI)
Normal at onset (CT); Cerebral
edema (MRI, 2 d later)
THERAPY PHN; Antibiotics, BCAA
infusion and lactulose
PHN; BCAA infusion
(first coma); Mannitol;
Propofol and thiopental;
UCD therapy: stop protein
intake, high caloric intake,
L-Arg and CVVHDF
PHN, BCAA infusion;
Mannitol; Lactulose;
Antibiotics; UCD therapy:
SB, SPB and L-Arg
PHN; Phenytoin,
thiopental and curare;
UCD therapy: SB, SPB,
L-Arg and CVVHDF
PHN; Midazolam, metamizole
and hypothermia; BCAA infusion;
UCD therapy: stop protein intake,
high caloric intake, SPB, L-Arg and HD
Date of starting UCD therapy (days from onset) None 2nd d from second coma 3rd d 3rd d 7th d
Ammonia after UCD therapy None Never normalized Normal Normal Normal
Time for normalisation of ammonia under UCD therapy None None 4 d 1 d and a half 4 d
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, − not available, Pplasma, Uurine, CT computed tomography, d days, MRI magnetic resonance imaging, PHN parenteral hydration and
nutrition, BCAA branched chain amino acids, UCD urea cycle disorder, L-Arg L-arginine, CVVHDF continuous veno venous hemodiafiltration, SB sodium benzoate, SPB sodium phenylbutyrate, HD hemodialysis.
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Table 3 OTC gene mutations identified in adult OTCD patients with fatal encephalopathy
Patient
(sex; origin)
Mutation Exon Functional domain Comment Mutation
reference
Genetic family testing
Pt 1 (M; Italy) c.119G > T
(p.Arg40Leu)
2 Polar/CP binding domain (S1) CpG dinucleotide This
report
Three HT females: mother (76 y),
two nieces (13 and 22 y);
HM brother (50 y); WT sister
Pt 2 (M; Italy
and Japan)
c.119G > A
(p.Arg40His)
2 Polar/CP binding domain (S1) CpG dinucleotide; protein
degradation under certain
conditions; reported OTC
activity 6%
[17] Not performed
Pt 3 (M; Italy) c.314G > A
(p.Gly105Glu)
4 Polar/CP binding domain (turn) - This
report
HT mother (43 y);
HM grandfather (80 y);
WT brother
Pt 4 (M; Italy) c.622G > A
(p.Ala208Thr)
6 Equatorial/ORN binding domain
(H6)
CpG dinucleotide; reported
OTC activity 4%
[19] HT daughter (36 y)
Pt 5 (F; Italy) c.829C > T
(p.Arg277Trp)
8 Equatorial/ORN binding domain
(H9), flexible loop
CpG dinucleotide;
increased km for ORN;
reported OTC activity 5%
[20] Three HT females: mother (72 y),
sister (42 y) and niece (18 y);
six WT females and two WT males
Abbreviations: M male, F female, CP carbamyl phosphate, ORN ornithine, S strand or β-sheet, H α-helix, HT heterozygous, HM hemizygous, WT wild type, y years of
family members at the time of the proband’s acute episode.
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classical UCD including OTCD adults has been recently
reported [3]. However, no information is available indi-
cating the number of asymptomatic adult probands, or
their clinical course or the potential role of precipitant fac-
tors. Herein we report previously asymptomatic OTCD
adults to provide clues that might help recognition of
OTCD in adult age, and discuss the environmental factors
triggering initial and fatal hyperammonemic episodes.
The patient’s dietary preference for vegetables should
be considered as an important clinical clue, since volun-
tary protein avoidance is a characteristic eating behavior
that UCD patients adopt in order to avoid postprandial
headache or drowsiness [22].
Special attention should be given to the biological spe-
cimen collection, since biochemical marker determin-
ation is essential for UCD diagnosis, especially during
the acute episodes and also in patients with fatalFigure 1 OTC enzyme three dimensional structure mapping the new m
the OTC monomer. B) Trimeric assembly of OTC enzyme indicating position 1
are colored green, blue and magenta and position 105 is colored yellow in eaoutcome. In patients with acute unexplained encephal-
opathy is mandatory to perform blood gas analysis and
plasma ammonia measurement as part of the basic
work-up, even in the absence of liver dysfunction. Detec-
tion of respiratory alkalosis and hyperammonemia must
address further metabolic investigations on plasma and
urine to confirm or exclude UCD, without delaying the
specific hyperammonemia treatment, as clinical outcome
strictly correlates with the duration and peak level of
hyperammonemia [4]. Analysis of plasma amino acids
and urine orotic acid should be urgently performed in a
specialist centre at initial detection of hyperammonemia.
Glutamine levels and increased urinary orotic acid are
the main biochemical markers for acute-phase OTCD.
Citrulline and arginine levels are often low in LO-OTCD
but may be normal outside the acute phase [23,24].
In Pt 3 the normal values of both plasma glutamine
and urinary orotic acid, detected at first measurementissense variants. A) 3D visualization of the new p.Arg40Leu mutation in
05 involved in the new p.Gly105Glu mutation. Constituent monomers
ch of them.
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with the suspicion of OTCD, but a final OTCD diagnosis
was reached through molecular analysis. In Pt 2 we
found high plasma and urinary levels of lactate during
his comatose state. This finding is in line with Snodgrass
2004 [25] who reported lactic acidosis only in advanced
phase of OTCD.
It has been reported that during acute OTCD episodes
coagulopathy may occasionally appear as a consequence
of liver dysfunction [26]. More recently, it has been
emphasised that coagulation abnormalities are previ-
ously unidentified complications of OTCD also in a re-
mission state [27]. In light of these findings, a diagnosis
of OTCD and other UCD should be actively sought in
any child or adult presenting with coagulopathy and/or
liver failure of undetermined etiologies [28]. In Pt 2 we
detected prothrombin deficiency, but is unknown if it
was an expression of chronic hepatitis, or of OTCD or
of both. In this patient the diagnostic process was se-
verely complicated and delayed by many misdiagnoses,
such as portosystemic shunt, as frequently described by
Japanese authors [29].
Hyperlysinemia and hyperprolinemia, which have been
reported as negative prognostic factors for OTCD [30],
have been detected in 3 patients in our series. However,
hyperprolinemia in Pt 2 may be secondary to hyperlacta-
cidemia, probably because proline oxidase is inhibited by
lactic acid [31].Molecular analysis and mutational correlations to
LO-OTCD
Molecular analysis is the first choice method for con-
firming an OTCD diagnosis, thus it would be advanta-
geous that the emergency department staff promptly
consult a clinical biochemical geneticist or clinical gen-
eticist, even at the initial presentation if possible (see links:
http://www.orpha.net/consor/cgi-bin/index.php, https://www.
eimd-registry.org/ and https://rarediseasesnetwork.epi.usf.
edu/ucdc/index.htm). However, most of the OTC mutations
are private and variants whose pathogenicity is unknown and
sometimes difficult to ascertained are frequently found. Thus,
in silico analysis, by combining different tools, may be useful
for predicting variant effects.
The novel p.Arg40Leu mutation leads to destabilization
of the OTC enzyme by the loss of a salt bridge or of MoRF
(Molecular Recognition Feature) binding. The MoRFs rep-
resent a class of disordered regions that provide molecular
recognition and binding functions to other proteins and
undergo disorder-to-order transitions upon specific bind-
ings [32]. The in silico results for p.Arg40Leu are in line
with the suggestion that mutations affecting codons on
the convex face of the OTC trimer, such as Arg 40, may
alter the conformation of the C-terminus and henceinterfere with its interaction with other proteins or the
membrane [11].
The novel p.Gly105Glu mutation leads to a destabilization
of local structures because of changes in solvent accessibility
and in charge and steric hindrance, finally resulting in a per-
turbation of the trimer assembly. Therefore, p.Gly105Glu
seems to lead to a partially functional enzyme.
The known p.Arg40His, p.Ala208Thr and p.Arg277Trp
mutations are also responsible for partial OTC enzyme
deficiency. Although the enzymatic assay was not per-
formed for the novel p.Arg40Leu, in silico data indicating
the biochemical similitude between the two mutations p.
Arg40Leu and p.Arg40His and the comparable clinical
presentation of patients carrying such mutations, suggest
that p.Arg40Leu is also correlated with residual enzymatic
activity and LO-OTCD.
Four out of five identified mutations affect CpG
islands and three of them arise in arginine. Arginine has
a high mutational score, likely because four of the six co-
dons encoding it contain CpG dinucleotides, which rep-
resent mutational hot spots [2]. Since the novel p.
Arg40Leu mutation affects the same CpG island as the
known recurrent c.119G > A (p.Arg40His) mutation, it is
probable that p.Arg40Leu might also occur in additional
families.
Correlation of OTCD unmasking with environmental
factors
The acute disease expression in the patients we reported
results from a combination of genetic and environmental
factors. Exposure to new environmental or stress factors
may induce an unusual nitrogen load or a significant
catabolic event, which can briskly affect the patients’
homeostasis and interfere with residual OTC activity,
making it no longer sufficient to remove the increased
amount of waste nitrogen generated. Some medications
may also cause hepatic toxicity and subsequent add-
itional impairment of already overwhelmed OTC activity
in the liver. The identification in the patients’ families of
several healthy adults of both genders harboring the
same mutations as the patients, corroborates the hy-
pothesis that these mutations cause their pathogenetic
consequences only when particular environmental con-
ditions arise.
Cortisone is a glucocorticoid hormone with many
therapeutic uses. High circulating concentrations of glu-
cocorticoids are known to have a general catabolic effect
by primarily enhancing protein turnover [33]. There are
at least four reports of OTCD adults who developed
acute hyperammonemic coma following steroid adminis-
tration [5,34-36].
Fasting and surgery are commonly considered danger-
ous conditions for OTCD patients since they cause
metabolic stress and are often accompanied by reduced
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ous proteins [5,37-39]. Moreover, a role of high protein
diets (e.g. Atkins’ diet) in unmasking adult-onset OTCD
has been previously described [40].
Besides a high protein intake as an obvious triggering
factor in Pt 3, the possible precipitating role of monoso-
dium glutamate (MSG) consumption, which is especially
used in Asian cuisine as a flavor enhancer, could also be
considered. MSG has been reported to accelerate gastric
emptying of a protein-rich meal in humans, stimulating
secretions from the exocrine and endocrine systems and
leading to increased plasma glutamine concentrations
[41]. Therefore, MSG ingested by our patient could have
contributed to a more rapid overload of nitrogen and
glutamine.
Chemotherapics are among the medications causing
hepatic toxicity and affecting protein catabolism. Their
side effects on the oro-gastrointestinal tract are indeed re-
sponsible for impairing dietary protein absorption and
consequently accelerating degradation of endogenous pro-
teins. A postchemotherapy hyperammonemic encephalop-
athy emulating OTCD has been described as a distinct
syndrome of hyperammonemia in two young women with
hepatocellular carcinoma, who resulted mutation-negative
to OTC [42,43]. Since insertion/deletions or deep intronic
mutations were not excluded, OTCD unmasked by
chemotherapy could still be possible in these patients.
The precipitating environmental factor for the female
patient is not obvious, but a potential role of sex hor-
mones or hormonal drugs seems to be very likely. Menses
are considered precipitants for acute hyperammonemia in
UCD [44] and a relationship between sex hormones and
ureagenesis in a woman with UCD has been reported
[45]. At least three hypotheses might explain the OTCD
unmasking in our patient: a) the physiological changes of
the endometrium during the menstrual cycle, which pro-
duce large amounts of waste nitrogen and which may ex-
plain the drowsiness occurring in conjunction with
menses; b) the direct action of endogenous sex hormones
and/or hormonal drugs on the urea cycle by modulation
of enzymatic expression and function; c) the toxic effects
of infertility medication resulting in worsening of hepatic
function, since these drugs are primarily metabolized in
the liver.
An additional precipitant for the metabolic decompen-
sation in our patients might have been parenteral nutri-
tion, which provides more proteins than the patient
usually expends entirely [46].
Conclusions
The diagnosis of OTCD in adults may be difficult, as clin-
ical manifestations are non-specific and often episodic and
laboratory findings can be normal outside the acute phase.
Since LO-OTCD can be hidden and suddenly becomesymptomatic under specific environmental factors, early
suspicion/diagnosis is crucial to providing effective treat-
ment in probands and to helping prevent clinical out-
bursts in other family members. This report raises
awareness of emergency department staff in considering
OTCD in the differential diagnosis of sudden neurological
and behavioural disorders associated with hyperammone-
mia at any age and in both genders. Molecular analysis is
the method of choice for confirming an OTCD diagnosis,
for uncovering the carrier status in at risk family members
and for providing genetic counselling and prenatal diagno-
sis. Future efforts should be aimed at further widening the
knowledge about combined effect of genetic factors (i.e.
mutations in the OTC gene, variants in modifier genes or
epigenetic features) and environmental conditions in de-
termining the phenotypic expression of OTCD.
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